• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用增殖细胞核抗原分析甲状旁腺功能亢进患者甲状旁腺的增殖活性。

Analysis of proliferative activity of the parathyroid glands using proliferating cell nuclear antigen in patients with hyperparathyroidism.

作者信息

Yamaguchi S, Yachiku S, Morikawa M

机构信息

Department of Urology, Asahikawa Medical College, Hokkaido, Japan.

出版信息

J Clin Endocrinol Metab. 1997 Aug;82(8):2681-8. doi: 10.1210/jcem.82.8.4117.

DOI:10.1210/jcem.82.8.4117
PMID:9253354
Abstract

To elucidate the cellular proliferative kinetics of the parathyroidal gland in patients with hyperparathyroidism, we investigated the expression of proliferating cell nuclear antigen (PCNA) in parathyroidal tissues using an immunohistochemical procedure. The PCNA labeling index (LI; maximum LI, maximal stained area; average LI, evenly distributed stained area) indicating cellular proliferative activity was defined as the number of PCNA-positive cells per 1000 parathyroid cells in the region of interest. We used these indexes to compare and investigate the proliferative activity of parathyroid cells under various conditions. The specimens used for the study were 42 parathyroid glands from 21 patients with primary hyperparathyroidism (19 cases of adenoma and 2 cases of primary hyperplasia due to multiple endocrine neoplasia type 1) and 129 parathyroid glands from 32 patients with secondary hyperparathyroidism. An additional 40 parathyroid glands resected during thyroid surgery of 30 normocalcemic patients were used as normal controls. In normally functioning parathyroids, a small number of cells in the growth phase were found. In primary hyperparathyroidism, proliferative activity was highest in the adenoma followed by primary hyperplasia. In contrast, the PCNA LIs showed a low value in the normal rim of the adenoma and normal glands resected as biopsy specimens from adenoma patients. We, therefore, assumed that proliferative activity was suppressed in these cells compared with that in normally functioning glands. In secondary hyperparathyroidism, when the cell component of the parathyroid tissues was divided into five types, PCNA immunoreactivity was lowest in the dark chief cells. Proliferative activity in cells of the oxyphil series was the same or higher than that in the clear chief cells or vacuolated chief cells. When classified according to the structure of the parathyroid glands, cell proliferation was significantly higher in the nodular type than in the diffuse type (maximum LI, 176 +/- 231 vs. 38.3 +/- 55.7; average LI, 120 +/- 188 vs. 24.8 +/- 43.5; mean +/- SD; P < 0.001). More PCNA-immunoreactive cells were found in autotransplanted glands with recurrence than in glands resected during the initial surgery. To summarize the PCNA expression classified according to the pathological types of hyperparathyroidism, the PCNA LIs were highest in secondary hyperplasia (maximum LI, 144 +/- 212; average LI, 96.0 +/- 169) and adenoma (maximum LI, 102 +/- 81.7; average LI, 67.5 +/- 67.7), followed by primary hyperplasia (maximum LI, 25.0 +/- 25.4; average LI, 19.2 +/- 22.2) and normal glands (maximum LI, 13.6 +/- 23.9; average LI, 4.40 +/- 8.90). These findings suggest that the cellular proliferative kinetics of the parathyroid gland differ depending on the type of hyperparathyroidism, glandular structure, and cell components. As the detection method of intranuclear expression of PCNA in cells is too sensitive, we should be careful not to overestimate the number of cells in the proliferative cycle. However, these results could not have been obtained using a conventional method such as DNA analysis by flow cytometry.

摘要

为阐明甲状旁腺功能亢进患者甲状旁腺的细胞增殖动力学,我们采用免疫组织化学方法研究了甲状旁腺组织中增殖细胞核抗原(PCNA)的表达。将表示细胞增殖活性的PCNA标记指数(LI;最大LI,最大染色面积;平均LI,均匀分布的染色面积)定义为感兴趣区域内每1000个甲状旁腺细胞中PCNA阳性细胞的数量。我们使用这些指数来比较和研究不同条件下甲状旁腺细胞的增殖活性。用于该研究的标本包括来自21例原发性甲状旁腺功能亢进患者的42个甲状旁腺(19例腺瘤和2例因多发性内分泌腺瘤1型导致的原发性增生)以及来自32例继发性甲状旁腺功能亢进患者的129个甲状旁腺。另外,将30例血钙正常患者甲状腺手术中切除的40个甲状旁腺用作正常对照。在功能正常的甲状旁腺中,发现少数处于生长阶段的细胞。在原发性甲状旁腺功能亢进中,腺瘤中的增殖活性最高,其次是原发性增生。相比之下,腺瘤的正常边缘以及作为腺瘤患者活检标本切除的正常腺体中的PCNA LI值较低。因此,我们推测与功能正常的腺体相比,这些细胞中的增殖活性受到抑制。在继发性甲状旁腺功能亢进中,当将甲状旁腺组织的细胞成分分为五种类型时,PCNA免疫反应性在暗主细胞中最低。嗜酸性细胞系列细胞的增殖活性与亮主细胞或空泡状主细胞相同或更高。根据甲状旁腺的结构分类时,结节型中的细胞增殖明显高于弥漫型(最大LI,176±231对38.3±55.7;平均LI,120±188对24.8±43.5;均值±标准差;P<0.001)。在复发的自体移植腺体中发现的PCNA免疫反应性细胞比初次手术时切除的腺体中更多。总结根据甲状旁腺功能亢进的病理类型分类的PCNA表达,PCNA LI在继发性增生(最大LI,144±212;平均LI,96.0±169)和腺瘤(最大LI,102±81.7;平均LI,67.5±67.7)中最高,其次是原发性增生(最大LI,25.0±25.4;平均LI,19.2±22.2)和正常腺体(最大LI,13.6±23.9;平均LI,4.40±8.90)。这些发现表明,甲状旁腺的细胞增殖动力学因甲状旁腺功能亢进的类型、腺体结构和细胞成分而异。由于细胞中PCNA核内表达的检测方法过于敏感,我们应注意不要高估增殖周期中的细胞数量。然而,使用诸如流式细胞术进行DNA分析等传统方法无法获得这些结果。

相似文献

1
Analysis of proliferative activity of the parathyroid glands using proliferating cell nuclear antigen in patients with hyperparathyroidism.使用增殖细胞核抗原分析甲状旁腺功能亢进患者甲状旁腺的增殖活性。
J Clin Endocrinol Metab. 1997 Aug;82(8):2681-8. doi: 10.1210/jcem.82.8.4117.
2
Morphological evaluation of parathyroid adenomas and immunohistochemical analysis of PCNA and Ki-67 proliferation markers.甲状旁腺腺瘤的形态学评估以及PCNA和Ki-67增殖标志物的免疫组化分析。
Turk Patoloji Derg. 2011;27(3):215-20. doi: 10.5146/tjpath.2011.01078.
3
Nodular foci in parathyroid adenomas and hyperplasias: an immunohistochemical analysis of proliferative activity.甲状旁腺腺瘤和增生中的结节状病灶:增殖活性的免疫组织化学分析
Hum Pathol. 1994 Oct;25(10):1050-6. doi: 10.1016/0046-8177(94)90064-7.
4
Nuclear DNA content, S-phase fraction analysis and expression of proliferating cell nuclear antigen (PCNA) of normal and hyperplastic/neoplastic parathyroid glands.正常及增生/肿瘤性甲状旁腺的核DNA含量、S期分数分析及增殖细胞核抗原(PCNA)表达
Fukushima J Med Sci. 1997 Jun;43(1):41-50.
5
Assessment of proliferative activity of glandular cells in hyperfunctioning parathyroid gland using flow cytometric and immunohistochemical methods.使用流式细胞术和免疫组织化学方法评估功能亢进甲状旁腺中腺细胞的增殖活性。
World J Surg. 1996 Mar-Apr;20(3):361-6; discussion 367. doi: 10.1007/s002689900059.
6
[The use of flow cytometry in the study of parathyroid hyperplasia and adenomas].[流式细胞术在甲状旁腺增生和腺瘤研究中的应用]
Pathologica. 1992 Jul-Aug;84(1092):459-65.
7
Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism.原发性和尿毒症继发性甲状旁腺功能亢进症中细胞外钙敏感受体免疫染色减少。
J Clin Endocrinol Metab. 1996 Apr;81(4):1598-606. doi: 10.1210/jcem.81.4.8636374.
8
[Study on the cellular proliferation and endocrine activity of the parathyroid gland in hyperparathyroidism].[甲状旁腺功能亢进症中甲状旁腺的细胞增殖和内分泌活性研究]
Nihon Hinyokika Gakkai Zasshi. 1993 Aug;84(8):1424-31. doi: 10.5980/jpnjurol1989.84.1424.
9
Calcium-sensing receptor and apoptosis in parathyroid hyperplasia of patients with secondary hyperparathyroidism.继发性甲状旁腺功能亢进患者甲状旁腺增生中钙敏感受体与细胞凋亡
J Int Med Res. 2013 Feb;41(1):97-105. doi: 10.1177/0300060513476600. Epub 2013 Jan 28.
10
Parathyroid adenomas and glands in normocalcemic hyperparathyroidism. A light microscopic study.血钙正常的原发性甲状旁腺功能亢进症中的甲状旁腺腺瘤与腺体。一项光镜研究。
Am J Pathol. 1976 Jun;83(3):475-84.

引用本文的文献

1
Identification of key biomarkers based on the proliferation of secondary hyperparathyroidism by bioinformatics analysis and machine learning.基于生物信息学分析和机器学习的继发性甲状旁腺功能亢进增殖的关键生物标志物的鉴定。
PeerJ. 2023 Jul 10;11:e15633. doi: 10.7717/peerj.15633. eCollection 2023.
2
Diagnosis, management, histology and genetics of sporadic primary hyperparathyroidism: old knowledge with new tricks.散发性原发性甲状旁腺功能亢进症的诊断、管理、组织学及遗传学:旧知识与新方法
Endocr Connect. 2018 Feb;7(2):R56-R68. doi: 10.1530/EC-17-0283. Epub 2018 Jan 12.
3
Optimal scan time for evaluation of parathyroid adenoma with [(18)F]-fluorocholine PET/CT.
使用[(18)F] - 氟胆碱PET/CT评估甲状旁腺腺瘤的最佳扫描时间。
Radiol Oncol. 2015 Nov 27;49(4):327-33. doi: 10.1515/raon-2015-0016. eCollection 2015 Dec.
4
Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs.肾病继发性甲状旁腺功能亢进的治疗:关于拟钙剂和维生素D类似物的应用,我们已知和未知的情况
Int J Nephrol Renovasc Dis. 2008;1:5-17. doi: 10.2147/ijnrd.s4368. Epub 2008 Nov 13.
5
Cyclooxygenase 2 promotes parathyroid hyperplasia in ESRD.环氧化酶 2 促进慢性肾脏病患者甲状旁腺增生。
J Am Soc Nephrol. 2011 Apr;22(4):664-72. doi: 10.1681/ASN.2010060594. Epub 2011 Feb 18.
6
Selected markers of proliferation and apoptosis in the parathyroid lesions: a spatial visualization and quantification.甲状旁腺病变中增殖和凋亡的选定标志物:空间可视化与定量分析
J Mol Histol. 2008 Oct;39(5):509-17. doi: 10.1007/s10735-008-9190-1. Epub 2008 Aug 24.
7
Disorders of the parathyroid glands.甲状旁腺疾病。
J Feline Med Surg. 2004 Aug;6(4):259-69. doi: 10.1016/j.jfms.2003.08.004.
8
Decreased expression of calcium receptor in parathyroid tissue in patients with hyperparathyroidism secondary to chronic renal failure.慢性肾衰竭继发性甲状旁腺功能亢进患者甲状旁腺组织中钙受体表达降低。
Endocr Pathol. 2003 Spring;14(1):61-70. doi: 10.1385/ep:14:1:61.